Mirae Asset offers asset management, securities and fixed income investment advisory services to mutual funds and foreign investment trusts.
Business Model:
Revenue: $1B
Employees: 10,001-999,999
Address: 67, Suha-dong
City: Jung-gu
State: seoul teugbyeolsi
Zip: 100-210
Country: KR
Mirae Asset offers asset management, securities and fixed income investment advisory services to mutual funds and foreign investment trusts.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2013 | Posco | Private Equity Round | 223.6M |
7/2022 | Eka.Care | Series A | 0 |
4/2021 | Arrail Dental Clinic | Series E | 0 |
2/2022 | Sobot | Series D | 0 |
9/2020 | XtalPi | Series C | 318.8M |
8/2021 | FalconX | Series C | 210M |
12/2021 | Spatial | Series B | 25M |
4/2018 | AppOnboard | Series A | 0 |
7/2022 | Jai Kisan | Series B | 0 |
11/2021 | Carro | Series C | 100M |
6/2020 | JW Therapeutics | Series B | 0 |
11/2021 | Impossible Foods | Series H | 500M |
11/2021 | NAVER Z | Series B | 0 |
1/2019 | Zolo | Series B | 30M |
10/2022 | GOPIZZA | Series C | 0 |
7/2020 | Zolo | Series C | 56M |
8/2021 | Inceptio Technology | Series B | 0 |
9/2021 | Statespace | Series C | 0 |
1/2022 | Animoca Brands | Series A | 358.9M |
8/2018 | Mesh Korea | Series E | 33.1M |
9/2022 | PI Industries Ltd. | Post-IPO Secondary | 0 |
5/2022 | Vyriad | Series B | 0 |
11/2022 | Casma Therapeutics | Series C | 46M |
9/2018 | 4D Molecular Therapeutics | Series B | 0 |
8/2018 | Shadowfax | Series C | 22M |
12/2021 | Figment | Series C | 0 |
6/2023 | AvoMD | Seed Round | 0 |
10/2022 | Farizon Auto | Seed Round | 300M |
10/2016 | BBB | Series A | 5M |
8/2020 | Impossible Foods | Series G | 200M |
5/2022 | Nextbillion.ai | Series B | 0 |
11/2022 | X-EPIC | Series B | - |
8/2021 | Sonoma BioTherapeutics | Series B | 0 |
1/2023 | Ensoma | Series B | 0 |
12/2019 | FinAccel | Series C | 90M |
9/2020 | Immotor | Series C | - |
3/2018 | TCR2 | Series B | 0 |
3/2018 | Hua Medicine | Series D | 0 |
10/2018 | Nebula Genomics | Series A | 0 |
7/2021 | AvoMD | Pre Seed Round | 3M |
4/2019 | Vividion Therapeutics | Series B | 82M |
1/2022 | Pavilion Data Systems, Inc. | Series D | 0 |
5/2021 | Akili Interactive Labs | Series D | 0 |
7/2021 | HappyFresh | Series D | 0 |
3/2022 | Faze | Series A | 100M |
4/2018 | Didi | Private Equity Round | 264.8M |
6/2017 | Naver | Post-IPO Equity | 438.2M |
11/2019 | Acticor Biotech | Series B | 0 |
9/2022 | Nextbillion.ai | Series B | 3M |
3/2020 | Impossible Foods | Series F | 500M |
9/2021 | BYJU’S | Series F | 148.2M |
5/2019 | AmazeVR | Series A | 7M |
1/2016 | Everspin | Series A | 1.9M |
8/2021 | Apeel Sciences | Series E | 0 |
10/2022 | Kredivo Holdings | Series D | 0 |
3/2022 | OpenSpace | Series D | 0 |
12/2021 | Daki | Series B | 260M |
8/2021 | Immunitas Therapeutics | Series B | 0 |
4/2022 | AppsForBharat | Secondary Market | 9.5M |
5/2017 | BIOMx | Series A | 24M |
10/2021 | CarDekho | Series E | 0 |
7/2022 | Jai Kisan | Series B | 0 |
7/2022 | Eka.Care | Series A | 0 |
5/2022 | Nextbillion.ai | Series B | 0 |
5/2022 | Vyriad | Series B | 0 |
4/2022 | AppsForBharat | Secondary Market | 0 |
3/2022 | Faze | Series A | 0 |
3/2022 | OpenSpace | Series D | 0 |
2/2022 | Sobot | Series D | 0 |
1/2022 | Pavilion Data Systems, Inc. | Series D | 0 |
1/2022 | Animoca Brands | Series C | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2021 | Investment Fund | $35M | 6/2017 | Post-IPO Equity | 1 | $441.1M |
Naver Naver |
10/2021 | Debt Financing | 2 | $450M |
Goldman Sachs Deutsche Bank Goldman Sachs Deutsche Bank |
8/2020 | Investment Fund | $32.6M | 6/2017 | Post-IPO Equity | 1 | $441.1M |
Naver Naver |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|